>_ QFI Terminal
Terminal › Stocks › PPCB

Propanc Biopharma, Inc. (PPCB) Stock

Healthcare · Biotechnology · AU
$3.00 +971.43%
Last updated Nov 12, 2026 10:46 UTC

PPCB Key Statistics

Market Cap$45.51M
P/E (TTM)-0.22
P/S (TTM)1,521.73
P/B (TTM)3.83
Revenue (TTM)$29,904.00
EPS (TTM)$-13.54
Dividend Yield—
ROE (TTM)-465.17%
Net Margin-9,999.99%
Gross Margin0.44%
52W High$9.11
52W Low$0.95
Analyst View—
Price Target—
Employees1
Volume3,652

About Propanc Biopharma, Inc.

Propanc Biopharma, Inc., a biopharmaceutical company, focuses on the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. Its lead product is PRP, a formulation that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes acting synergistically. The company has a research collaboration with University of JaƩn to commence the POP1 joint drug discovery program. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia.

CEO: James Nathanielsz. Company website

PPCB — Frequently Asked Questions

What is the PPCB stock price today?

Propanc Biopharma, Inc. (PPCB) trades at $3.00, up 971.43% on the day, as of Nov 12, 2026 10:46 UTC.

What is Propanc Biopharma, Inc.'s market cap?

Propanc Biopharma, Inc. has a market capitalisation of $45.51M, calculated from the live PPCB share price and shares outstanding.

What is the P/E ratio of PPCB?

PPCB has no meaningful price-to-earnings ratio: Propanc Biopharma, Inc. lost $13.54 per share over the last twelve months, and a P/E is only defined on positive earnings.

How much revenue does Propanc Biopharma, Inc. make?

Propanc Biopharma, Inc. generated revenue of $29,904.00 over the trailing twelve months, which puts the stock at 1,521.73 times sales.

What is the 52-week range for PPCB?

PPCB has traded between $0.95 and $9.11 over the past 52 weeks, and the last price is 67.1% below that high.

Is Propanc Biopharma, Inc. profitable?

No. Propanc Biopharma, Inc. is loss-making, with a net margin of -9,999.99% over the trailing twelve months.

What sector is Propanc Biopharma, Inc. in?

Propanc Biopharma, Inc. is classified under the Healthcare sector and the Biotechnology industry, and is domiciled in AU .

Who is the CEO of Propanc Biopharma, Inc.?

James Nathanielsz is the chief executive of Propanc Biopharma, Inc., which employs 1 people.

Where can I track PPCB in real time?

QFI Terminal shows PPCB with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.

See PPCB live in QFI Terminal

Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.

Open PPCB in Terminal See plans

Biotechnology stocks

REGN Regeneron Pharmaceuticals, Inc. VRTX Vertex Pharmaceuticals Incorporated ONC BeOne Medicines AG INCY Incyte Corporation ALNY Alnylam Pharmaceuticals, Inc. JAZZ Jazz Pharmaceuticals plc ARGX argenx SE GMAB Genmab A/S NBIX Neurocrine Biosciences, Inc. BMRN BioMarin Pharmaceutical Inc. UTHR United Therapeutics Corporation CDT CDT Equity Inc. MRNA Moderna, Inc. EXEL Exelixis, Inc. BNTX BioNTech SE SRPT Sarepta Therapeutics, Inc. HALO Halozyme Therapeutics, Inc. INSM Insmed Incorporated MDGL Madrigal Pharmaceuticals, Inc. TECH Bio-Techne Corporation ASND Ascendis Pharma A/S CAI Caris Life Sciences, Inc. IONS Ionis Pharmaceuticals, Inc. BBIO BridgeBio Pharma, Inc.

More Healthcare stocks

UNH UnitedHealth Group Incorporated CVS CVS Health Corp. MCK McKesson Corporation COR Cencora, Inc. NVO Novo Nordisk A/S CI Cigna Corporation CAH Cardinal Health, Inc. CNC Centene Corp. ELV Elevance Health Inc. HUM Humana Inc. JNJ Johnson & Johnson LLY Eli Lilly and Company HCA HCA Healthcare, Inc. MRK Merck & Co., Inc. ABBV AbbVie Inc. PFE Pfizer Inc.